XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026)

XOMA Royalty's (XOMA) quarterly Non-Current Deffered Revenue came in at $2.9 million in Q1 2026, down 29.97% year-on-year from $4.1 million in Q1 2025, and down 10.43% quarter-over-quarter from $3.2 million in Q4 2025.

XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends

XOMA Royalty has disclosed Non-Current Deffered Revenue across 17 years of filings, most recently posting $2.9 million for Q1 2026.

  • Non-Current Deffered Revenue for Q1 2026 came in at $2.9 million, down 29.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 29.97% YoY), and the FY2025 annual result was $3.2 million, down 27.6% from the prior year.
  • Non-Current Deffered Revenue came in at $2.9 million for Q1 2026 at XOMA Royalty, down from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $11.3 million in Q1 2022 to a low of $2.9 million in Q1 2026.
  • The 5-year median for Non-Current Deffered Revenue is $6.7 million (2024), against an average of $6.7 million.
  • Across the five-year window, Non-Current Deffered Revenue declined 13.59% in 2022 and sank 38.99% in 2024, its largest moves.
  • XOMA Royalty's Non-Current Deffered Revenue stood at $9.5 million in 2022, then slipped by 24.31% to $7.2 million in 2023, then tumbled by 38.99% to $4.4 million in 2024, then slipped by 27.6% to $3.2 million in 2025, then slipped by 10.43% to $2.9 million in 2026.
  • The last three Non-Current Deffered Revenue figures came in at $2.9 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn -
9 Abivax 95.45 Bn 95.45 Bn - -
10 XOMA Royalty 5.52 Mn -60.56 Mn - 2.86 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.86 Mn
Dec 31, 2025 3.19 Mn
Sep 30, 2025 3.47 Mn
Jun 30, 2025 3.67 Mn
Mar 31, 2025 4.08 Mn
Dec 31, 2024 4.41 Mn
Sep 30, 2024 5.59 Mn
Jun 30, 2024 5.96 Mn
Mar 31, 2024 6.69 Mn
Dec 31, 2023 7.23 Mn
Sep 30, 2023 7.80 Mn
Jun 30, 2023 8.45 Mn
Mar 31, 2023 9.04 Mn
Dec 31, 2022 9.55 Mn
Sep 30, 2022 10.38 Mn
Jun 30, 2022 10.84 Mn
Mar 31, 2022 11.35 Mn
Dec 31, 2021 11.69 Mn
Sep 30, 2021 12.31 Mn
Jun 30, 2021 12.73 Mn